Truth: Weight loss and fitness are not the same
Aging reflects a network of interacting processes, and current research increasingly emphasizes combinatorial strategies that integrate pharmacologic, metabolic, and lifestyle-based interventions
We work with you to see whats the least amount of the medication needed to support you in maintaining your best health. Who Might Consider Microdosing GLP-1s (and Who Shouldnt) GLP-1s in general are typically recommended and usually only covered by insurance for people with obesity (defined as a BMI greater than 30) as well as those with a BMI greater than 27 and one or more weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol
FDA Approval vs Compounding vs Research Use In real-world practice, this may be the biggest differentiator: Sermorelin: Previously marketed (Geref), now often encountered via compounding rather than as an FDA-approved commercial product (FDA, 2013)
The animal science is solid, but no large human trials have been completed, it's not FDA-approved, and the company that developed it walked away from it in the early 2000s
While primarily indicated for type 2 diabetes, ongoing research explores its potential benefits in weight management and cardiovascular health, offering a promising outlook for broader therapeutic applications
